Log in to your Inderes Free account to see all free content on this page.
Prostatype Genomics
0.38 SEK
-0.26 %
Less than 1K followers
PROGEN
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
-0.26 %
-54.98 %
-70.20 %
+26.67 %
-32.86 %
-73.43 %
-99.39 %
-99.95 %
-99.90 %
Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.
Read moreMarket cap
22.49M SEK
Turnover
44.1K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
30.6.
2026
General meeting '26
23.7.
2026
Interim report Q2'26
11.2.
2027
Annual report '26
All
Press releases
ShowingAll content types
Prostatype Genomics AB announces the Board of Directors’ intention to resolve on a rights issue of units of approximately SEK 47.4 million
Prostatype Genomics publishes year-end report for 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio